KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Long-Term Investments (2018 - 2025)

Vir Biotechnology's Long-Term Investments history spans 7 years, with the latest figure at $314.6 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 65.55% year-over-year to $314.6 million; the TTM value through Dec 2025 reached $314.6 million, up 65.55%, while the annual FY2025 figure was $314.6 million, 65.55% up from the prior year.
  • Long-Term Investments for Q4 2025 was $314.6 million at Vir Biotechnology, up from $304.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $359.7 million in Q1 2024 and bottomed at $5.7 million in Q2 2021.
  • The 5-year median for Long-Term Investments is $190.0 million (2024), against an average of $169.7 million.
  • The largest YoY upside for Long-Term Investments was 1612.02% in 2022 against a maximum downside of 88.12% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $201.4 million in 2021, then crashed by 88.12% to $23.9 million in 2022, then soared by 339.98% to $105.3 million in 2023, then skyrocketed by 80.49% to $190.0 million in 2024, then soared by 65.55% to $314.6 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Long-Term Investments are $314.6 million (Q4 2025), $304.2 million (Q3 2025), and $286.1 million (Q2 2025).